VHPKQHR peptide modified magnetic mesoporous nanoparticles for MRI detection of atherosclerosis lesions
Source abstract
Abstract
Mortality attributable to atherosclerosis can be reduced significantly with timely diagnosis and treatment. It is meaningful to find a proper way to diagnose and prevent the progression of atherosclerosis. Vascular cell adhesion molecule-1 (VCAM-1) expressed by endothelial cells is a prominent marker of atherosclerotic plaques. There are a number of researches on VCAM-1 based probes for targeted imaging, but rarely on a system with both targeting and drug delivery. Here, we report a novel magnetic mesoporous silicon nanoparticle that is capable of drug delivery and targeting at atherosclerosis plaque. The nanoparticles were constructed using incorporated FITC (fluorescein isothiocyanate) and VHPKQHR peptide into Fe3O4@SiO2 (FITC-VHP-Fe3O4@SiO2). The FITC-VHP-Fe3O4@SiO2 nanoparticles showed great morphological characteristics, superior targeting ability, low toxicity and good biocompatibility in vitro and in vivo. The in vivo experiments showed that FITC-VHP-Fe3O4@SiO2 is a superior contrast agent of magnetic resonance imaging (MRI) for diagnosis of atherosclerosis plaques.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanocluster Synthesis and Applications · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
MOE Key Laboratory of Laser Life Science and Institute of Laser Life Science, South China Normal University
College of Biophotonics, South China Normal University
Guangzhou Universal Medical Imaging Diagnostic Center, Universal Medical Imaging
Department of Radiology, The Third Affiliated Hospital of Southern Medical University
Funding
National Natural Science Foundation of China · Science and Technology Project of Guangzhou
References (38)
Show source-provided references
1. 10.1161/CIRCRESAHA.115.30761110.1161/CIRCRESAHA.115.307611 ↗
2. 10.1016/S0002-9440(10)65646-510.1016/S0002-9440(10)65646-5 ↗
3. 10.1056/NEJMra121606310.1056/NEJMra1216063 ↗
4. 10.1586/14779072.5.1.6910.1586/14779072.5.1.69 ↗
5. 10.1016/j.atherosclerosis.2016.06.02810.1016/j.atherosclerosis.2016.06.028 ↗
6. 10.2147/IJN.S7650110.2147/IJN.S76501 ↗
7. 10.1016/j.apsb.2017.12.00210.1016/j.apsb.2017.12.002 ↗
8. 10.1161/01.ATV.18.5.84210.1161/01.ATV.18.5.842 ↗
9. 10.3109/10408363.2014.99206310.3109/10408363.2014.992063 ↗
10. 10.1194/jlr.R800032-JLR20010.1194/jlr.R800032-JLR200 ↗
11. 10.1111/j.1582-4934.2012.01552.x10.1111/j.1582-4934.2012.01552.x ↗
12. 10.1016/j.jcmg.2009.04.01610.1016/j.jcmg.2009.04.016 ↗
13. 10.1096/fj.11-18377210.1096/fj.11-183772 ↗
14. 10.1021/acs.molpharmaceut.7b0096110.1021/acs.molpharmaceut.7b00961 ↗
15. 10.1016/j.nano.2014.09.01410.1016/j.nano.2014.09.014 ↗
16. Zhang Y, Xu J. Mesoporous silica nanoparticle-based intelligent drug delivery system for bienzyme-responsive tumour targeting and controlled release. R Soc Open Sci. 2018;5:1–10.
17. 10.1080/10717544.2017.130947510.1080/10717544.2017.1309475 ↗
18. 10.1161/CIRCULATIONAHA.106.64638010.1161/CIRCULATIONAHA.106.646380 ↗
19. 10.1007/s11307-006-0043-610.1007/s11307-006-0043-6 ↗
20. 10.1016/j.mri.2016.08.01610.1016/j.mri.2016.08.016 ↗
21. 10.1021/acsnano.8b0336810.1021/acsnano.8b03368 ↗
22. 10.1385/CBB:40:3:28910.1385/CBB:40:3:289 ↗
23. 10.1161/CIRCRESAHA.112.26814410.1161/CIRCRESAHA.112.268144 ↗
24. 10.1177/153537021769311610.1177/1535370217693116 ↗
25. 10.1021/bc300330910.1021/bc3003309 ↗
26. 10.1186/s40580-018-0170-110.1186/s40580-018-0170-1 ↗
27. 10.1016/j.biomaterials.2014.06.05410.1016/j.biomaterials.2014.06.054 ↗
28. 10.7150/thno.2076710.7150/thno.20767 ↗
29. 10.1159/00032495110.1159/000324951 ↗
30. 10.1148/radiol.227201207110.1148/radiol.2272012071 ↗
31. 10.1093/eurheartj/ehq15010.1093/eurheartj/ehq150 ↗
32. 10.1053/j.semnuclmed.2018.07.00110.1053/j.semnuclmed.2018.07.001 ↗
33. 10.2174/221155521120101001210.2174/2211555211201010012 ↗
34. 10.1136/hrt.2005.07120910.1136/hrt.2005.071209 ↗
35. Libby MAP. Lipid lowering therapy in atherosclerosis. Semin Vasc Med. 2004;4:257–367.
36. 10.2147/IJN.S14631510.2147/IJN.S146315 ↗
37. 10.1590/abd1806-4841.2016398610.1590/abd1806-4841.20163986 ↗
38. 10.1080/1094291070158425210.1080/10942910701584252 ↗